RT Journal Article
SR Electronic
T1 Efficacy and Limitations of F-18-fluoro-2-deoxy-D-glucose Positron Emission Tomography to Differentiate Between Malignant and Benign Bone and Soft Tissue Tumors
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4065
OP 4072
DO 10.21873/anticanres.12696
VO 38
IS 7
A1 SHINJI MIWA
A1 TAKAFUMI MOCHIZUKI
A1 NORIO YAMAMOTO
A1 TOSHIHARU SHIRAI
A1 KATSUHIRO HAYASHI
A1 AKIHIKO TAKEUCHI
A1 HIROYUKI INATANI
A1 KENTARO IGARASHI
A1 TAKASHI HIGUCHI
A1 KENSAKU ABE
A1 YUTA TANIGUCHI
A1 HISAKI AIBA
A1 HIROKO IKEDA
A1 HIROYUKI TSUCHIYA
YR 2018
UL http://ar.iiarjournals.org/content/38/7/4065.abstract
AB Background/Aim: Positron emission tomography (PET) using 18fluorine-labelled fluorodeoxyglucose (FDG), is the most widely applied molecular imaging technique in oncology. The present study assessed the efficacy and limitations of FDG-PET by comparing FDG accumulation in bone and soft tissue lesions, as well as histopathological features. Patients and Methods: The study included 122 patients with 165 lesions, as assessed by histopathological examinations. The maximum standardized uptake values (SUVmax) of benign lesions were compared to those of primary, recurrent, or metastatic sarcomas, as well as those of other malignancies. Results: The sensitivity, specificity, and accuracy of SUVmax for differentiation between benign lesions and primary sarcomas were 67.9%, 92.9%, and 80.4%, respectively. There were no significant differences between benign lesions and recurrent or metastatic sarcomas. Conclusion: Although FDG-PET is a useful imaging modality to differentiate primary sarcomas from benign lesions, it is difficult to differentiate residual or metastatic sarcomas from benign lesions.